CY1106638T1 - Χαμηλα - υπερασβεστεμικα οξιμης αναλογα της 1αλφα, 25-διϋδροξυ βιταμινη d3 - Google Patents

Χαμηλα - υπερασβεστεμικα οξιμης αναλογα της 1αλφα, 25-διϋδροξυ βιταμινη d3

Info

Publication number
CY1106638T1
CY1106638T1 CY20071100741T CY071100741T CY1106638T1 CY 1106638 T1 CY1106638 T1 CY 1106638T1 CY 20071100741 T CY20071100741 T CY 20071100741T CY 071100741 T CY071100741 T CY 071100741T CY 1106638 T1 CY1106638 T1 CY 1106638T1
Authority
CY
Cyprus
Prior art keywords
dihydroxyvitamin
oxime
hypercalcemium
1alpha
low
Prior art date
Application number
CY20071100741T
Other languages
Greek (el)
English (en)
Inventor
Gary H. Posner
Jay A. White
Glenville Jones
Bethany Halford
Mehmet Kahraman
Heung Bae Jeon
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CY1106638T1 publication Critical patent/CY1106638T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20071100741T 2001-10-12 2007-06-04 Χαμηλα - υπερασβεστεμικα οξιμης αναλογα της 1αλφα, 25-διϋδροξυ βιταμινη d3 CY1106638T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32842801P 2001-10-12 2001-10-12
PCT/CA2002/001519 WO2003031400A1 (en) 2001-10-12 2002-10-11 Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3

Publications (1)

Publication Number Publication Date
CY1106638T1 true CY1106638T1 (el) 2012-01-25

Family

ID=23280940

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100741T CY1106638T1 (el) 2001-10-12 2007-06-04 Χαμηλα - υπερασβεστεμικα οξιμης αναλογα της 1αλφα, 25-διϋδροξυ βιταμινη d3

Country Status (11)

Country Link
US (1) US6982258B2 (cg-RX-API-DMAC10.html)
EP (1) EP1436257B1 (cg-RX-API-DMAC10.html)
JP (1) JP4436674B2 (cg-RX-API-DMAC10.html)
AT (1) ATE360000T1 (cg-RX-API-DMAC10.html)
CA (1) CA2463505C (cg-RX-API-DMAC10.html)
CY (1) CY1106638T1 (cg-RX-API-DMAC10.html)
DE (1) DE60219655T2 (cg-RX-API-DMAC10.html)
DK (1) DK1436257T3 (cg-RX-API-DMAC10.html)
ES (1) ES2283593T3 (cg-RX-API-DMAC10.html)
PT (1) PT1436257E (cg-RX-API-DMAC10.html)
WO (1) WO2003031400A1 (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
JP2004504295A (ja) 2000-07-18 2004-02-12 ボーン ケア インターナショナル インコーポレイテッド 安定化1α−ヒドロキシビタミンD
US20050059641A1 (en) * 2003-06-17 2005-03-17 Aphios Corporation Compositions and methods for treating and preventing cancer using analogs of vitamin D
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
JP2007537263A (ja) * 2004-05-10 2007-12-20 ノバセア インコーポレイティッド 活性ビタミンd化合物による動脈再狭窄の予防法
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2006074227A2 (en) * 2005-01-04 2006-07-13 Johns Hopkins University HIGHLY ANTIPROLIFERATIVE, LOW-CALCEMIC, ANALOGS OF THE HORMONE 1α, 25-DIHYDROXYVITAMIN D3 WITH CARBONYL SIDE CHAINS
WO2006113990A2 (en) * 2005-04-25 2006-11-02 Cytochroma Inc. LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1α ,25-DIHYDROXY VITAMIN D3
US20070122477A1 (en) * 2005-10-12 2007-05-31 Cytochroma, Inc. Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
WO2008131267A2 (en) * 2007-04-18 2008-10-30 Johns Hopkins University Low calcemic, highly antiproliferative, analogs of calcitriol
CA2683628C (en) * 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
EP2148685A4 (en) * 2007-04-25 2010-07-28 Cytochroma Inc METHODS AND COMPOUNDS FOR THERAPY BASED ON VITAMIN D
ES3047207T3 (en) 2007-04-25 2025-12-03 Opko Renal Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009120565A2 (en) 2008-03-25 2009-10-01 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US20100227414A1 (en) * 2009-03-05 2010-09-09 Trex Enterprises Corp. Affinity capture mass spectroscopy with a porous silicon biosensor
WO2011088209A2 (en) 2010-01-13 2011-07-21 Cytochroma Inc. 1-deoxy analogs of vitamin d-related compounds
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104557647B (zh) * 2015-01-13 2016-07-06 南京理工大学 维生素d肟类衍生物、合成方法及其应用
CN104945296B (zh) * 2015-06-09 2016-08-24 南京理工大学 一类芳香醛腙修饰的维生素d2衍生物、合成及其应用
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
CN117003679A (zh) * 2022-04-29 2023-11-07 南澳大利亚大学 新型抑制剂化合物
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481198A (en) * 1984-02-13 1984-11-06 Wisconsin Alumni Research Foundation Vitamin D metabolism inhibitor
GB9623569D0 (en) * 1996-11-13 1997-01-08 Immunodiagnostic Systems Ltd Vitamin D immumoassay systems

Also Published As

Publication number Publication date
US6982258B2 (en) 2006-01-03
JP2005536444A (ja) 2005-12-02
CA2463505A1 (en) 2003-04-17
DE60219655D1 (de) 2007-05-31
JP4436674B2 (ja) 2010-03-24
ES2283593T3 (es) 2007-11-01
US20030171342A1 (en) 2003-09-11
WO2003031400A1 (en) 2003-04-17
CA2463505C (en) 2011-07-12
PT1436257E (pt) 2007-05-31
EP1436257A1 (en) 2004-07-14
ATE360000T1 (de) 2007-05-15
DE60219655T2 (de) 2007-12-27
EP1436257B1 (en) 2007-04-18
DK1436257T3 (da) 2007-06-25

Similar Documents

Publication Publication Date Title
ATE360000T1 (de) Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung
ATE543796T1 (de) 24-sulfoximine vitamin d3 derivate
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
DK1379239T3 (da) N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
BR9804437A (pt) Compostos para a osteoporose
UY27450A1 (es) Preparación y uso de derivados de imidazol para el tratamiento de la obesidad
NO331013B1 (no) Nye forbindelser som er anti-inflammasjons, immunomodulerende og anti-proliferative midler, anvendelse av forbindelsene samt farmasoytisk preparat
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
IS6922A (is) Heterófjölhringjaefnasambönd og notkun þeirra semmetabótrópísk mótlyf gegn glútamat viðtökum
NO20051207L (no) Proteinkinaseinhibitorer og anvendelser derav
CY1107839T1 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
DK1767535T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
NO20031687L (no) Veksthormonsekretagoger
NO20073801L (no) Atineoplastiske kombinasjoner
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
NO20050122L (no) Prodrug av eksitasjonsaminosyrer
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
BRPI0610644B8 (pt) composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
WO2004054968A3 (en) 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
GT200600199A (es) Diarilsulfonas sulfonamidas y su uso
ATE281432T1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
DK1441724T3 (da) Fremgangsmåde til forögelse af endogene testosteronniveauer
ATE443044T1 (de) Tace inhibitoren
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları